Skip Navigation

PROMISING FUTURES.

At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide life-changing advances to patients with rare genetic diseases. Mostly children, our patients suffer from diseases so rare that the entire afflicted population may number as few as 5,000 worldwide. Often inherited, difficult to diagnose, and progressively debilitating, these conditions have been largely ignored — until BioMarin.

Understanding that time is critical, we develop and commercialize new treatments at a significantly faster rate than the industry average — which reflects the urgency we feel to help.

Throughout our history, our focus has remained the same: We are a place where people do work that delivers hope. We are committed to our people, our patients, and our purpose. And we are passionate about what we deliver.

FACTS & FIGURES

Forbes' Most Innovative Company 4 years in a row
50 plus Countries in which patients are treated
6 products in market
5 products in clinical pipeline
Rare Disease Day video, click enter to play video BioMarin focuses on the neglected diseases, the rare diseases that other companies don't want to touch. Yaw Asare-Aboagye, Senior Director, Clinical Data Management
Return to the top of the page